Opna Bio

Opna Bio receives FDA Fast Track designation for OPN-6602, an oral EP300/CBP inhibitor targeting key drivers of tumor growth and resistance, in multiple myeloma. opnabio.com/opna-bio-annou… #MultipleMyeloma #Oncology #DrugDevelopment

📄 Phase 1b results with our BET inhibitor zavabresib (OPN-2853) are now published in Cancer Chemotherapy and Pharmacology. The study demonstrated target engagement, tolerability and early clinical activity of zavabresib in solid tumors and lymphoma. link.springer.com/article/10.100…

Phase 1b results with zavabresib (OPN-2853) now published in Cancer Chemotherapy and Pharmacology. Study showed target engagement, tolerability and early signs of clinical activity in advanced solid tumors and lymphoma. link.springer.com/article/10.100…

Headed to ASH this weekend? Make sure to stop by our posters highlighting promising Phase 1 interim clinical data in myelofibrosis with OPN-2853 (12/8 6-8 pm) and preclinical data in multiple myeloma with OPN-6602 (12/7 5:30-7:30 pm). #ASH2024#myelofibrosis#multiplemyeloma

We have treated the first patient with OPN-6602 in our Phase 1 clinical study in relapsed or refractory multiple myeloma. Additionally, we have named Axel Bolte, MBA, MSc, to board director and Stephanie Oestreich, PhD, MPA, to board observer. lnkd.in/gdFS89Zg

Dr. Pan-Yu Chen presenting research at AACR on OPN-9840, an oral pan-TEAD inhibitor that demonstrated in vitro and in vivo efficacy in preclinical models of malignant mesothelioma. For more information on Opna’s presentations at AACR, see #AACR24#TEADinhibition#malignantmesothelioma" target="_blank" rel="nofollow noopener">opnabio.com/press-releases…

We presented research yesterday at AACR on OPN-6602, our EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical multiple myeloma models, showing 71% tumor growth inhibition in the OPM-2 MM model and >100% TGI in combo studies. #AACR24

During Multiple Myeloma month, Opna is raising awareness of this blood cancer which develops in plasma cells in the bone marrow. The company expects to begin a first-in-human Phase 1 trial with OPN-6602, a selective EP300/CBP bromodomain inhibitor, in MM patients later in 2024.

Sending warm wishes for a joyful holiday season to all! #oncologybiotech #EP300/CBP inhibition #FMRP

Are you attending AACR-NCI-EORTC in Boston next week? We’ll be presenting promising preclinical data on Opna’s EP300/CBP bromodomain inhibitors in metastatic castration-resistant prostate cancer. Abstract #CO85, 10/14, 12:30-4 pm ET #AACR-NCI-EORTC #mCRPC #EP300

Check out Opna's profile in BioCentury, detailing the discovery of the fragile X mental retardation protein (FMRP) as a new cancer target, and five oncology programs licensed from the former Plexxikon, including 2 clinical-stage assets. biocentury.com/article/646652… #FMRP #Phase2

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program - Fragile X Mental Retardation Protein (FMRP) - and Diversified Pipeline of Clinical and Preclinical Programs Acquired from Plexxikon. lnkd.in/gGEydBWV